Semaglutide Eligibility Across All Current Indications for US Adults.
作者信息
Shi Ivy, Khan Sadiya S, Yeh Robert W, Ho Jennifer E, Dahabreh Issa J, Kazi Dhruv S
机构信息
Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
出版信息
JAMA Cardiol. 2025 Jan 1;10(1):96-98. doi: 10.1001/jamacardio.2024.4657.
Abstract
摘要
相似文献
1
Semaglutide Eligibility Across All Current Indications for US Adults.司美格鲁肽在美国成年人所有现有适应症中的适用情况。
JAMA Cardiol. 2025 Jan 1;10(1):96-98. doi: 10.1001/jamacardio.2024.4657.
2
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.美国人群的资格以及司美格鲁肽治疗对肥胖患病率和心血管疾病事件的估计影响。
Cardiovasc Drugs Ther. 2025 Feb;39(1):75-84. doi: 10.1007/s10557-023-07488-3. Epub 2023 Aug 14.
3
Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.美国有资格接受司美格鲁肽治疗的超重和肥胖成年人在经济障碍方面的种族和民族差异。
J Am Heart Assoc. 2022 Oct 4;11(19):e025545. doi: 10.1161/JAHA.121.025545. Epub 2022 Sep 29.
4
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.司美格鲁肽2.4毫克对肥胖或超重且患有心血管疾病患者的人群水平影响：一项基于SELECT试验的建模研究
Diabetes Obes Metab. 2025 Jun;27(6):3442-3452. doi: 10.1111/dom.16370. Epub 2025 Apr 4.
5
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.替尔泊肽和司美格鲁肽对美国成年人的终生健康影响及成本效益
JAMA Health Forum. 2025 Mar 7;6(3):e245586. doi: 10.1001/jamahealthforum.2024.5586.
6
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.根据 SELECT 试验，在美国有资格使用司美格鲁肽的人群中，心血管事件减少。
Am Heart J. 2024 Oct;276:110-114. doi: 10.1016/j.ahj.2024.05.007. Epub 2024 Jul 30.
7
National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US.美国SELECT试验资格的全国和州估计及其对公共卫生的影响。
JAMA Netw Open. 2024 Jul 1;7(7):e2420105. doi: 10.1001/jamanetworkopen.2024.20105.
8
The Real-World Use of Semaglutide to Promote Weight Loss in Obese Adults With Hemodialysis: A Multicenter Cross-Sectional Descriptive Study.司美格鲁肽在接受血液透析的肥胖成人中促进体重减轻的真实世界应用：一项多中心横断面描述性研究。
Can J Kidney Health Dis. 2025 Mar 17;12:20543581251324588. doi: 10.1177/20543581251324588. eCollection 2025.
9
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.司美格鲁肽在急性冠状动脉综合征超重和肥胖患者中的适用性及实际意义。
Int J Cardiol. 2025 Mar 15;423:133028. doi: 10.1016/j.ijcard.2025.133028. Epub 2025 Jan 29.
10
Projections of Endovascular Therapy-Eligible Patients With Stroke for the US Population.美国人口中适合血管内治疗的卒中患者预测。
Stroke. 2024 Aug;55(8):2011-2019. doi: 10.1161/STROKEAHA.123.045766. Epub 2024 Jun 27.
引用本文的文献
1
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.胰高血糖素样肽-1受体激动剂对肥胖人群骨骼健康的影响。
Osteoporos Int. 2025 Sep 8. doi: 10.1007/s00198-025-07664-1.
2
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.司美格鲁肽和替尔泊肽用于射血分数保留的心力衰竭患者
JAMA. 2025 Aug 31. doi: 10.1001/jama.2025.14092.
3
Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans.医疗保险D部分计划中司美格鲁肽和替尔泊肽的覆盖范围及预先授权政策。
JAMA Netw Open. 2025 Aug 1;8(8):e2529842. doi: 10.1001/jamanetworkopen.2025.29842.
4
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.胰高血糖素样肽-1受体激动剂与肥胖成年人的癌症风险
JAMA Oncol. 2025 Aug 21. doi: 10.1001/jamaoncol.2025.2681.
5
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.支持胰高血糖素样肽-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会的联合咨询意见
Obes Pillars. 2025 Jun 3;15:100181. doi: 10.1016/j.obpill.2025.100181. eCollection 2025 Sep.
6
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.司美格鲁肽：治疗心血管-肾脏-代谢综合征的关键药物。
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
7
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.支持胰高血糖素样肽-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会联合咨询意见
Am J Lifestyle Med. 2025 May 30:15598276251344827. doi: 10.1177/15598276251344827.
8
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.支持GLP-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会联合发布的咨询意见
Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336.
9
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.代谢性疾病口腔生物大分子疗法的进展
Pharmaceutics. 2025 Feb 12;17(2):238. doi: 10.3390/pharmaceutics17020238.
本文引用的文献
1
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.基于美国心脏协会 PREVENT 心血管风险方程的他汀类药物和抗高血压治疗适应证的预计变化。
JAMA. 2024 Sep 24;332(12):989-1000. doi: 10.1001/jama.2024.12537.
2
Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable.民意调查：约12%的美国成年人使用过胰高血糖素样肽-1（GLP-1）药物，即便负担不起。
JAMA. 2024 Jul 2;332(1):8. doi: 10.1001/jama.2024.10333.
3
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
4
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.皮下司美格鲁肽与安慰剂作为强化行为疗法辅助手段对超重或肥胖成人体重的影响：STEP 3 随机临床试验。
JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
5
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.在治疗 2 型糖尿病方面，每周一次皮下注射司美格鲁肽的疗效、安全性和心血管结局比较：来自 SUSTAIN 1-7 试验的结果。
Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4.
Zotero 插件